1. In Vivo
  2. >>Archive

Corgentech/BMS: Finding Specialty Appeal in a Drug/Device Combo

Bristol-Myers Squibb is the latest Big Pharma to step into a specialty market, via a deal to co-promote a drug/device combination being developed by Corgentech. The product is meant to prevent vein graft failure common after bypass graft surgery in the heart and the legs. For the Big Pharma, the appeal of this specialty product is all about higher margins from lower costs, since it will be sold to surgeons in hospitals. The biotech originator wanted a partner to help it get to market faster, manage the product's life cycle, and handle quotidian tasks that add costs but not value to a small firm.

Big Pharmas seem to be waking up to the fact that there are only so many billion-dollar pills to be had. The evidence? Lately, companies that customarily dispatch thousands of sales reps have begun doing deals for specialty products geared towards small prescriber and patient bases. The attraction is uncomplicated: because specialty products can be sold with less fanfare and force than drugs that have to compete for share of voice among general practitioners, they can deliver better profit margins.

Pfizer Inc. with some 14,000 reps--the biggest pharmaceutical marketing force in the world—was one of the first major drugmakers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.